Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

1.15
+0.04003.60%
Post-market: 1.160.0100+0.87%19:34 EST
Volume:1.41M
Turnover:1.59M
Market Cap:132.66M
PE:-0.87
High:1.17
Open:1.12
Low:1.09
Close:1.11
52wk High:2.07
52wk Low:0.6611
Shares:115.35M
Float Shares:100.80M
Volume Ratio:1.32
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3180
EPS(LYR):-1.6384
ROE:-52.35%
ROA:-23.85%
PB:0.57
PE(LYR):-0.70

Loading ...

Company Profile

Company Name:
Fate Therapeutics
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
181
Office Location:
12278 Scripps Summit Drive,San Diego,California,United States
Zip Code:
92131
Fax:
- -
Introduction:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Directors

Name
Position
Bahram Valamehr
President,Chief Executive Officer,Chief Research and Development Officer and Director
William H. Rastetter
Chairman of the Board
Karin Jooss
Director
Matthew C. Abernethy
Director
Michael Lee
Director
Robert S. Epstein
Director
Shefali Agarwal
Director
Timothy P. Coughlin
Director
Yuan Xu
Director

Shareholders

Name
Position
Bahram Valamehr
President,Chief Executive Officer,Chief Research and Development Officer and Director
Kamal Adawi
Chief Financial Officer
Cindy R. Tahl
Chief Legal & Compliance Officer and Corporate Secretary